HC Wainwright Has Positive Forecast for CorMedix Q3 Earnings

CorMedix Inc (NASDAQ:CRMD) – Equities research analysts at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for CorMedix in a note issued to investors on Friday, August 8th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.33 per share for the quarter, up from their previous forecast of $0.23. HC Wainwright currently has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share.

Several other analysts have also issued reports on the company. D Boral Capital lowered CorMedix from a “strong-buy” rating to a “hold” rating in a report on Monday, June 30th. Royal Bank Of Canada raised CorMedix from an “outperform” rating to a “moderate buy” rating and boosted their price target for the company from $13.00 to $17.00 in a report on Friday, June 20th. D. Boral Capital lowered CorMedix from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Needham & Company LLC boosted their price target on CorMedix from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, June 24th. Finally, Wall Street Zen downgraded CorMedix from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $16.71.

CorMedix Stock Performance

NASDAQ:CRMD opened at $10.07 on Monday. The stock has a 50-day simple moving average of $12.47 and a two-hundred day simple moving average of $10.77. CorMedix has a 52-week low of $3.61 and a 52-week high of $17.43. The firm has a market capitalization of $751.73 million, a PE ratio of 13.43 and a beta of 1.71.

CorMedix (NASDAQ:CRMD) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.08. CorMedix had a return on equity of 42.73% and a net margin of 42.11%. The business had revenue of $39.74 million during the quarter, compared to analyst estimates of $29.88 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. CorMedix’s revenue for the quarter was up 4830.1% on a year-over-year basis.

Hedge Funds Weigh In On CorMedix

Several large investors have recently made changes to their positions in CRMD. Elliott Investment Management L.P. lifted its position in shares of CorMedix by 85.1% in the fourth quarter. Elliott Investment Management L.P. now owns 2,870,632 shares of the company’s stock valued at $23,252,000 after acquiring an additional 1,320,109 shares in the last quarter. Palisades Investment Partners LLC bought a new position in CorMedix during the fourth quarter valued at approximately $2,949,000. J. Goldman & Co LP boosted its stake in CorMedix by 221.1% during the fourth quarter. J. Goldman & Co LP now owns 457,320 shares of the company’s stock valued at $3,704,000 after buying an additional 314,880 shares during the last quarter. Vanguard Group Inc. boosted its stake in CorMedix by 10.1% during the fourth quarter. Vanguard Group Inc. now owns 3,378,191 shares of the company’s stock valued at $27,363,000 after buying an additional 309,514 shares during the last quarter. Finally, Nuveen LLC bought a new position in CorMedix during the first quarter valued at approximately $1,692,000. 34.18% of the stock is currently owned by hedge funds and other institutional investors.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.